Trial Profile
Phase II Study of Lenalidomide Maintenance in Patients With High Risk AML in Remission
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 17 Dec 2021 Status changed from recruiting to completed.
- 15 Jan 2021 Results (n=28) assessing lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission, published in the Cancer
- 23 May 2019 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.